Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

By sjmartinez • February 7, 2023

Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023 Feb 5:e14539. doi: 10.1111/nmo.14539. Epub ahead of print. PMID: 36740814.

Tags: abdominal pain, cannabinoid receptor agonists, cannabinoids, Digestive Diseases, Irritable Bowel Syndrome, olorinab, Publications

Large North American Multicenter Experience on Endoscopic Submucosal Dissection of Rectal Neoplasms Extending to the Dentate Line

Sharma NR, Gopakumar H, Malik TF, Khan A, Dahiya DS, Vohra I, Zelt CM, Rumple A, Flanagan M, Mendoza-Ladd A, Adam AA, Saeed AB, Othman[...]

Luminal LPS is transported across murine small intestine by a caveolin-1 dependent endocytic mechanism induced by chronic feeding of a Western-style diet

Akiba Y, Pokala N, Kaunitz JD. Luminal LPS is transported across murine small intestine by a caveolin-1 dependent endocytic mechanism induced by chronic feeding of[...]

JPEN Journal Club 96. Scoping reviews

Koretz RL. JPEN Journal Club 96. Scoping reviews. JPEN J Parenter Enteral Nutr. 2025 Oct 28. doi: 10.1002/jpen.70025. Epub ahead of print. PMID: 41153060.